In preclinical studies using a KRAS mutant non-small-cell lung cancer (NSCLC) xenograft model, NBF-006 demonstrated significant tumor suppression and prolonged survival, with 70–80 % of the administered dose being internalized by tumor tissues and was well tolerated by the animal models. This evidence concerns the gene KRAS and neoplasm.